TNF Inhibitor denied as duplicate or overlapping therapy by Anthem Blue Cross?

Anthem CA uses CarelonRx PBM. Adalimumab biosimilar preferred. CA SB 853 protects against non-medical switching for stable patients.

Cite CA SB 853 (Continuity of Care) — protects stable patients from non-medical switches. Cite CG-DRUG-64 by name. CarelonRx exception process.

## Why Anthem Blue Cross Denies TNF Inhibitors as Duplicate Therapy

Anthem Blue Cross may issue a duplicate-therapy denial when its utilization-management system detects that another biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) is already active on your profile — even if that agent belongs to a different mechanistic class. The insurer's position is that you cannot receive therapeutic benefit from two agents acting on overlapping inflammatory pathways simultaneously, or that the clinical rationale for switching has not been adequately documented.

This denial is frequently appealable because TNF inhibitors are a distinct class with a specific mechanism, and clinicians routinely use, switch, or cycle within and across biologic classes based on individual patient response, tolerability, and disease activity. The key is demonstrating that the prescriber made a deliberate, medically justified decision — not an administrative error.

## Federal Appeal Framework

You have layered federal protections:

• Internal appeal (ERISA §503 / ACA §2719): Submit a written internal appeal within the timeframe printed on your denial notice (typically 180 days for ERISA plans, though confirm yours).
• External independent review: After exhausting the internal process — or if Anthem fails to decide within the required timeframe — you may request an Independent Review Organization (IRO) review. ACA-regulated plans must comply. The external-review window is generally up to approximately four months from the date of final internal denial; verify the exact deadline on your denial letter.
• Expedited review: If a standard timeline would seriously jeopardize your health, request expedited internal and external review simultaneously.

## Documentation to Gather

1. Diagnosis confirmation — chart notes, specialist letters, and any objective disease-activity measures establishing the condition for which the TNF inhibitor is prescribed. 2. Current and prior therapy history — complete list of all biologics and conventional DMARDs tried, with start/stop dates and documented reasons for discontinuation (inadequate response, adverse effect, contraindication per your physician's judgment). 3. Clinical severity documentation — recent office notes, lab markers, imaging, or validated scoring tools your physician uses to track disease activity. 4. Prescriber medical-necessity letter — a letter from your prescribing clinician explaining why the TNF inhibitor is medically necessary and why the concurrently listed agent either (a) is being discontinued, (b) serves a distinct clinical purpose, or (c) has already been tried and failed. 5. Anthem's own coverage policy — download the current version from Anthem's provider or member portal; verify the exact criteria your physician must address.

## Criteria-Mapping Structure

Build a point-by-point response table:

| Anthem Policy Requirement | Supporting Chart Evidence | |---|---| | [Copy each requirement verbatim from Anthem's published coverage policy] | [Cite the exact chart note, date, and clinician statement that satisfies it] |

For the duplicate-therapy denial specifically, your prescriber should address: - Whether the previously active agent is being discontinued and why - Why the clinical presentation requires a TNF inhibitor specifically, referencing applicable guidelines from the relevant professional society (e.g., ACR, EULAR, or the applicable specialty guideline organization) - How the FDA-approved prescribing information for the requested TNF inhibitor supports this use

Obtain the exact dosing, eligibility thresholds, and clinical criteria from the FDA-approved prescribing label and Anthem's published medical/coverage policy before submitting your appeal.